C4
C4X.F Onxeo SA
- Market cap
- EUR 270M
- P/E
- -
- P/B
- 115.66x
- ROE
- -236.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is C4X.F undervalued?
Graham numberThe Graham number of Onxeo SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Onxeo SA fundamental analysis
No fundamental analysis for Onxeo SA yet.
Onxeo SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Onxeo SA
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjug…
Full company profileOnxeo SA financial statements
Onxeo SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.42M | 9.51M | 6.13M | 4.29M | 1.78M | 4.06M | 1.44M | 1.80M | 1.79M | 2.57M |
| Gross Profit | 3.77M | 8.87M | 5.91M | 3.94M | 1.43M | 3.69M | 929K | 1.27M | 1.28M | 1.73M |
| Operating Income | -23.2M | -66.4M | -15.6M | -15.8M | -7.81M | -5.58M | -17.1M | -19.1M | -16.5M | -550K |
| EBITDA | - | -25.5M | -947K | -9.62M | 3.42M | -4.49M | -17.1M | -18.4M | -12.1M | 542K |
| Net Income | -22.7M | -59.1M | -9.40M | -33.7M | 1.09M | -5.94M | -19.6M | -20.3M | -23.9M | -4.90M |
| EPS | - | -1.16 | -0.18 | -0.55 | 0.01 | -0.06 | -0.18 | -0.13 | -0.16 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 125M | 78.1M | 63.3M | 37.6M | 46.5M | 53.1M | 43.1M | 35.3M | 17.9M | 15.2M |
| Total Liabilities | 31.0M | 28.2M | 17.8M | 20.4M | 17.5M | 20.1M | 20.8M | 20.5M | 26.2M | 13.2M |
| Shareholders' Equity | 94.1M | 49.9M | 45.4M | 17.2M | 29.0M | 32.9M | 22.3M | 14.8M | -8.93M | 2.08M |
| Cash & Short-term Investments | 23.9M | 14.3M | 11.3M | 5.71M | 14.5M | 17.9M | 14.6M | 6.82M | 1.18M | 1.05M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -17.6M | -28.3M | -11.3M | -7.70M | -4.68M | -8.57M | -9.44M | -17.4M | -8.37M | 1.84M |
| Capital Expenditure | 545K | 65.0K | 45.0K | 26.0K | 119K | 139K | 488K | 182K | 319K | 1.32M |
| Free Cash Flow | - | -28.3M | -11.3M | -7.73M | -4.80M | -8.71M | -9.93M | -17.6M | -8.69M | 521K |
| Ratios | ||||||||||
| ROE | -24.1% | -118.4% | -20.7% | -196.1% | 3.8% | -18.0% | -87.8% | -137.4% | - | -236.0% |
| ROA | -18.1% | -75.7% | -14.9% | -89.6% | 2.3% | -11.2% | -45.4% | -57.7% | -133.4% | -32.2% |
| Net Profit Margin | -512.5% | -621.5% | -153.4% | -786.6% | 61.3% | -146.2% | -1,355.6% | -1,130.2% | -1,334.0% | -190.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Onxeo SA dividends
Onxeo SA has not paid dividends in the last 10 fiscal years.
Who owns Onxeo SA
- Insiders 29.94%
- Institutions 37.45%
- Public & others 32.61%
- Shares outstanding 588M
- Free float 147M
Onxeo SA company profile
- Company name
- Onxeo SA
- Ticker
- C4X.F
- ISIN
- FR0010095596
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Fiscal year end
- December
- Address
- 49, boulevard du GEnEral Martial Valin, Paris, France, 75015
- Phone
- 33 1 45 58 76 00
- Website
- valeriotx.com
About Onxeo SA
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjugates, and chimeric antigen receptors. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Onxeo SA management
2- Dr. Gilles Besin Ph.D.CEO & Director
- Mr. Wael Jdey Ph.D.CTO & Director